Adoption of streamlined breast cancer treatment has stagnated, study finds

Key points
- Accelerated partial breast irradiation was designed to be a faster, more convenient, and potentially safer way for many women with breast cancer to reduce their mortality risk and help keep their cancer from returning after surgery.
- Accelerated partial breast irradiation was created as an alternative to traditional radiation therapy for women with breast cancer who have had a lumpectomy or breast-conserving surgery.
- But a new study shows that the availability of the approach is failing to reduce the percentage of early-stage breast cancer patients who do not receive the radiation treatment that could save their lives.
- Both forms of radiation therapy aim to prevent the spread of any cancer cells that may remain after tumor removal.
Accelerated partial breast irradiation was designed to be a faster, more convenient, and potentially safer way for many women with breast cancer to reduce their mortality risk and help keep their cancer from returning after surgery. But a new study shows that the availability of the approach is failing to reduce the percentage of early-stage breast cancer patients who do not receive the radiation treatment that could save their lives.
Streamlined Care
Accelerated partial breast irradiation was created as an alternative to traditional radiation therapy for women with breast cancer who have had a lumpectomy or breast-conserving surgery. Both forms of radiation therapy aim to prevent the spread of any cancer cells that may remain after tumor removal. Traditional radiation treatment requires weeks of daily treatment, and the radiation can damage the lungs and heart; accelerated partial breast irradiation, on the other hand, condenses the treatments into only five days and can avoid some of the toxicities and tissue damage associated with the traditional approach. As such, it was hoped the availability of the accelerated approach would reduce the percentage of women who did not receive radiation.
"The problem is that [traditional] radiation therapy is a long-course treatment. Normally you see your radiation oncologist every day for five to seven weeks. Each treatment is only a few minutes, but it's not convenient at all for a lot of patients," explained researcher Nengliang (Aaron) Yao, PhD, of the University of Virginia School of Medicine's Department of Public Health Sciences. "This new therapy is actually improving convenience and reducing toxicity, and has become more accessible over time, but you don't see an improvement in adherence to radiation therapy after lumpectomy."
Alarming Statistic
Yao and Abram Recht, MD, of Harvard Medical School, looked at data from the 2014 Surveillance, Epidemiology and End Results (SEER) database, which collects information from 18 cancer registries covering approximately 28 percent of the U.S. population. The researchers identified 309,429 women who were diagnosed with breast cancer between January 2000 and June 2011. They found that approximately 14 percent of early-stage breast cancer patients did not receive radiation treatments after breast conserving surgery over the course of the study period.
Accelerated partial breast irradiation was first developed in the late 1990s. Use increased rapidly from 0.2 percent in 2000 to about 3.1 percent in 2008. Medicare began reimbursing for the procedure in 2004, and in 2009, the American Association of Radiation Oncologists issued a consensus statement to provide guidance for patients and physicians regarding the use of accelerated partial breast irradiation. But that guideline was not followed by an increase in its adoption, the researchers found. Instead, use has leveled off. The availability of the treatment, they determined, has not statistically reduced the percentage of women who receive a lumpectomy who do not receive radiation.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsThe factor that could influence future breast cancer treatment
Australian scientists have shown in the laboratory how a 'transcription factor' causes breast cancer cells to develop an aggressive subtype that lacks sensitivity to estrogen and does not respond to known anti-estrogen…
30 December 2012
NewsTGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute…
7 December 2012
NewsCombination treatment may improve survival of breast cancer patients with brain metastases
dding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus,…




